HRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.40%

Insider Buying (Last 12 Months): $3,667,489.28

Insider Selling (Last 12 Months): $0.00

Heron Therapeutics Insider Trading History Chart

Heron Therapeutics Share Price & Price History

^$2.55

▼ -0.1 (-3.77%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

Did You Get Your Free Bitcoin Yet?

From Crypto Swap Profits | Ad

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

Heron Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/16/2023	Craig A Collard	CEO	Buy	150,000	$0.92	$138,000.00	186,496
11/16/2023	Ira Duarte	CFO	Buy	85,000	$0.89	$75,650.00	85,000
11/16/2023	William P Forbes	EVP	Buy	50,000	$0.94	$47,000.00	54,000
7/21/2023	Adam Morgan	Director	Buy	2,486,744	$1.37	$3,406,839.28	6,986,744
5/3/2022	Kimberly Manhard	EVP	Sell	1,504	$4.76	$7,159.04	10,872
12/21/2021	Christian Waage	Director	Sell	300	$9.73	$2,919.00
9/21/2021	Christian Waage	Director	Sell	300	$12.31	$3,693.00
6/21/2021	Christian Waage	Director	Sell	300	$15.20	$4,560.00	3,800
5/3/2021	Kimberly Manhard	EVP	Sell	1,529	$17.66	$27,002.14	3,163

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for Heron Therapeutics (NASDAQ:HRTX)

80.01% of Heron Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Heron Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/18/2024	Diversified Trust Co	23,966	$66K	0.0%	N/A	0.016%
4/16/2024	Congress Park Capital LLC	1,644,785	$4.56M	2.0%	-8.6%	1.094%
4/5/2024	Los Angeles Capital Management LLC	493,264	$1.37M	0.0%	-4.1%	0.328%
2/15/2024	Orchard Capital Management LLC	2,243,426	$3.81M	1.2%	+4.7%	1.495%
2/9/2024	JW Asset Management LLC	2,292,418	$3.90M	2.2%	-4.8%	1.528%
2/9/2024	Franklin Resources Inc.	6,404,795	$10.89M	0.0%	-8.0%	4.268%
2/9/2024	D.A. Davidson & CO.	30,100	$51K	0.0%	-25.9%	0.020%
2/8/2024	Richmond Brothers Inc.	296,706	$0.50M	0.9%	+188.0%	0.198%
2/8/2024	Panagora Asset Management Inc.	139,113	$0.24M	0.0%	N/A	0.093%
2/7/2024	Monaco Asset Management SAM	2,226,475	$3.79M	1.1%	+219.5%	1.484%
2/6/2024	Los Angeles Capital Management LLC	514,377	$0.87M	0.0%	+49.9%	0.343%
2/5/2024	Victory Capital Management Inc.	19,929	$34K	0.0%	+30.2%	0.013%
2/5/2024	Pekin Hardy Strauss Inc.	36,470	$62K	0.0%	-38.3%	0.024%
1/31/2024	Knights of Columbus Asset Advisors LLC	83,482	$0.14M	0.0%	+100.0%	0.056%
1/30/2024	ACT Advisors LLC.	22,145	$38K	0.0%	N/A	0.015%
1/19/2024	Congress Park Capital LLC	1,798,650	$3.06M	1.5%	+205.3%	1.199%
1/16/2024	Raymond James Financial Services Advisors Inc.	48,309	$82K	0.0%	+61.2%	0.032%
11/15/2023	Tejara Capital Ltd	2,109,681	$2.17M	1.2%	+28.6%	1.499%
11/15/2023	Rubric Capital Management LP	26,713,503	$27.52M	1.0%	+127.3%	18.978%
11/15/2023	Adage Capital Partners GP L.L.C.	2,000,000	$2.06M	0.0%	+100.0%	1.421%
11/13/2023	Tejara Capital Ltd	2,109,681	$2.17M	1.6%	+28.6%	1.499%
11/9/2023	JW Asset Management LLC	2,407,418	$2.48M	1.1%	+9.1%	1.710%
11/8/2023	D.A. Davidson & CO.	40,600	$42K	0.0%	-84.2%	0.029%
11/8/2023	Pekin Hardy Strauss Inc.	59,095	$61K	0.0%	-44.3%	0.042%
11/7/2023	Monaco Asset Management SAM	696,908	$0.72M	0.2%	+72.1%	0.495%
11/7/2023	CM Management LLC	450,000	$0.46M	0.5%	-10.0%	0.320%
11/7/2023	New York State Common Retirement Fund	1,094,441	$1.13M	0.0%	-1.5%	0.778%
11/3/2023	Richmond Brothers Inc.	103,009	$0.11M	0.2%	+142.9%	0.073%
11/1/2023	Jacob Asset Management of New York LLC	327,450	$0.34M	0.5%	+18.2%	0.233%
10/27/2023	Allspring Global Investments Holdings LLC	41,034	$42K	0.0%	-30.4%	0.029%
10/24/2023	Bank of New York Mellon Corp	353,395	$0.36M	0.0%	+5.8%	0.251%
10/24/2023	Dakota Wealth Management	53,315	$55K	0.0%	N/A	0.038%
10/23/2023	Commonwealth Equity Services LLC	314,826	$0.32M	0.0%	+5.5%	0.224%
10/19/2023	Apeiron RIA LLC	83,000	$85K	0.0%	+59.6%	0.059%
10/13/2023	SG Americas Securities LLC	30,560	$31K	0.0%	N/A	0.022%
10/13/2023	Congress Park Capital LLC	589,150	$0.61M	0.3%	+15.2%	0.419%
9/21/2023	Barclays PLC	57,233	$65K	0.0%	-42.1%	0.041%
8/14/2023	X Square Capital LLC	31,185	$36K	0.0%	-78.9%	0.026%
8/14/2023	ArrowMark Colorado Holdings LLC	26,373	$31K	0.0%	-99.2%	0.022%
8/14/2023	Great Point Partners LLC	4,737,368	$5.50M	1.1%	-18.6%	3.957%
8/14/2023	Jefferies Financial Group Inc.	1,290,924	$1.50M	0.0%	N/A	1.078%
8/14/2023	Deep Track Capital LP	2,086,704	$2.42M	0.1%	-35.5%	1.482%
8/14/2023	Palisade Capital Management LP	4,143,649	$4.81M	0.1%	+4.4%	3.461%
8/14/2023	Graham Capital Management L.P.	169,148	$0.20M	0.0%	+576.4%	0.141%
8/11/2023	Searle & CO.	78,250	$0.13M	0.0%	+23.7%	0.065%
8/11/2023	Richmond Brothers Inc.	42,405	$49K	0.1%	N/A	0.035%
8/11/2023	JW Asset Management LLC	2,207,418	$2.56M	0.9%	N/A	1.844%
8/11/2023	Quinn Opportunity Partners LLC	72,097	$84K	0.0%	-21.7%	0.060%
8/11/2023	Franklin Resources Inc.	7,458,052	$8.65M	0.0%	-37.2%	6.230%
8/11/2023	Tejara Capital Ltd	1,640,133	$1.90M	0.9%	-1.6%	1.370%
8/11/2023	D.A. Davidson & CO.	256,407	$0.30M	0.0%	+15.8%	0.214%
8/10/2023	Jacob Asset Management of New York LLC	277,015	$0.32M	0.4%	-15.2%	0.231%
8/8/2023	Fisher Asset Management LLC	349,239	$0.41M	0.0%	-13.4%	0.292%
8/8/2023	Pekin Hardy Strauss Inc.	106,145	$0.12M	0.0%	-81.4%	0.089%
8/8/2023	Monaco Asset Management SAM	405,000	$0.47M	0.1%	N/A	0.338%
8/4/2023	CM Management LLC	500,000	$0.58M	0.6%	+42.9%	0.418%
8/3/2023	Los Angeles Capital Management LLC	339,474	$0.39M	0.0%	-51.9%	0.284%
7/25/2023	Raymond James Financial Services Advisors Inc.	32,950	$38K	0.0%	N/A	0.028%
7/24/2023	Allspring Global Investments Holdings LLC	58,935	$68K	0.0%	+85.8%	0.049%
7/20/2023	Apeiron RIA LLC	52,000	$60K	0.0%	+57.6%	0.043%
7/19/2023	Grimes & Company Inc.	47,804	$55K	0.0%	+26.8%	0.040%
7/18/2023	Allspring Global Investments Holdings LLC	58,935	$68K	0.0%	+85.8%	0.049%
7/14/2023	Congress Park Capital LLC	511,250	$0.59M	0.3%	+59.4%	0.427%
6/14/2023	State Board of Administration of Florida Retirement System	40,705	$61K	0.0%	-79.4%	0.034%
6/1/2023	Searle & CO.	63,250	$0.15M	0.0%	+90.2%	0.053%
5/16/2023	Great Point Partners LLC	5,817,368	$8.78M	1.7%	-8.5%	4.877%
5/15/2023	Quinn Opportunity Partners LLC	92,097	$0.14M	0.0%	N/A	0.077%
5/12/2023	Tejara Capital Ltd	1,667,519	$2.52M	1.3%	+237.8%	1.398%
5/11/2023	Jacob Asset Management of New York LLC	326,657	$0.49M	0.6%	+22.3%	0.274%
5/11/2023	M&T Bank Corp	89,280	$0.13M	0.0%	-39.8%	0.075%
5/10/2023	Simplify Asset Management Inc.	306,590	$0.46M	0.1%	N/A	0.257%
5/8/2023	Palisade Capital Management LP	3,970,286	$6M	0.2%	+4.9%	3.329%
5/8/2023	CM Management LLC	350,000	$0.53M	0.6%	+40.0%	0.293%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	32,615	$49K	0.0%	+49.4%	0.027%
5/4/2023	Los Angeles Capital Management LLC	705,677	$1.07M	0.0%	+320.9%	0.592%
4/28/2023	SG Americas Securities LLC	100,968	$0.15M	0.0%	N/A	0.085%
4/28/2023	Zweig DiMenna Associates LLC	121,630	$0.18M	0.0%	-13.6%	0.102%
4/27/2023	Arizona State Retirement System	34,448	$52K	0.0%	+18.9%	0.029%
4/25/2023	D.A. Davidson & CO.	221,445	$0.33M	0.0%	+27.4%	0.186%
4/20/2023	Grimes & Company Inc.	37,698	$57K	0.0%	+139.2%	0.032%
4/20/2023	Congress Park Capital LLC	320,660	$0.48M	0.3%	+23.3%	0.269%
4/13/2023	Apeiron RIA LLC	33,000	$50K	0.0%	N/A	0.028%
4/13/2023	Allspring Global Investments Holdings LLC	31,712	$48K	0.0%	+63.1%	0.027%
3/24/2023	Palisade Capital Management LP	3,785,895	$9.47M	0.2%	+11.7%	3.184%
2/15/2023	Tang Capital Management LLC	3,755,934	$9.39M	1.4%	-45.1%	3.159%
2/14/2023	Palisade Capital Management LLC NJ	3,785,895	$9.47M	0.3%	+11.7%	3.184%
2/13/2023	Pekin Hardy Strauss Inc.	571,855	$1.43M	0.2%	-11.1%	0.481%
2/13/2023	GSA Capital Partners LLP	116,574	$0.29M	0.0%	+34.8%	0.098%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	63,371	$0.16M	0.0%	-72.3%	0.053%
2/10/2023	Franklin Resources Inc.	11,867,780	$29.67M	0.0%	-0.1%	9.982%
2/10/2023	HRT Financial LP	439,384	$1.10M	0.0%	+15.5%	0.370%
2/10/2023	Cheyne Capital Management UK LLP	318,008	$0.80M	1.4%	N/A	0.267%
2/9/2023	CM Management LLC	250,000	$0.63M	0.7%	-9.1%	0.210%
2/8/2023	Pier 88 Investment Partners LLC	60,000	$0.15M	0.0%	+116.6%	0.050%
2/8/2023	Swiss National Bank	247,800	$0.62M	0.0%	-11.1%	0.208%
2/7/2023	State Board of Administration of Florida Retirement System	197,917	$0.50M	0.0%	+386.2%	0.166%
2/6/2023	Los Angeles Capital Management LLC	167,653	$0.42M	0.0%	-3.1%	0.141%
2/3/2023	D.A. Davidson & CO.	173,795	$0.43M	0.0%	-11.7%	0.146%
2/3/2023	Fisher Asset Management LLC	403,228	$1.01M	0.0%	+122.9%	0.339%
2/2/2023	X Square Capital LLC	147,862	$0.37M	0.2%	+179.7%	0.124%

Data available starting January 2016

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Today's Range

Now: $2.55

$2.46

$2.66

50 Day Range

MA: $2.75

$2.36

$3.06

52 Week Range

Now: $2.55

$0.50

$3.22

Volume

2,197,081 shs

Average Volume

2,790,822 shs

Market Capitalization

$383.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Who are the company insiders with the largest holdings of Heron Therapeutics?: Heron Therapeutics' top insider shareholders include:
Adam Morgan (Director)
Craig A Collard (CEO)
Ira Duarte (CFO)
William P Forbes (EVP)
Kimberly Manhard (EVP)
Learn More about top insider investors at Heron Therapeutics.
Who are the major institutional investors of Heron Therapeutics?: Heron Therapeutics' top institutional shareholders include:
Congress Park Capital LLC — 1.09%
Los Angeles Capital Management LLC — 0.33%
Diversified Trust Co — 0.02%
Learn More about top institutional investors of Heron Therapeutics stock.
Which institutional investors are selling Heron Therapeutics stock?: Within the last quarter, HRTX stock was sold by these institutional investors:
Congress Park Capital LLC
Los Angeles Capital Management LLC
Which institutional investors are buying Heron Therapeutics stock?: In the previous quarter, HRTX stock was bought by institutional investors including:
Diversified Trust Co
Within the last year, these company insiders have bought Heron Therapeutics stock:
Adam Morgan (Director)
Craig A Collard (CEO)
Ira Duarte (CFO)
William P Forbes (EVP)
Learn More investors buying Heron Therapeutics stock.